Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exact Sciences Corporation: A Checklist For Investors

ACADIA Pharma

Amarin Corporation Plc

Exelixis

Jazz Pharmaceuticals

Seagen

Tumultuous market conditions discounted the stock prices of these leading biotech companies.

6 Quality Biotech Stocks on Sale Now

The companies will complement its precision oncology products.

Exact Sciences Acquires 2 Cancer Diagnostic Companies

This cancer diagnostics company has produced one breakthrough product and is developing more.

Why Exact Sciences Dropped 13.2% in February

It's loaded up with a new round of financing and its stock price is hovering at recent lows, meaning investors may want to grab shares of this growing cancer diagnostics company.

Investors Should Revisit Exact Sciences Now

Labcorp Holdings Inc

QIAGEN

Thermo Fisher Scientific

The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

Bio-Rad Laboratories

There's a strong case to be made for both companies, but which one is a better investment?

Better Buy: Exact Sciences vs. Bio-Rad Laboratories

Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.

Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y

The diagnostics company easily topped Q4 revenue and earnings expectations. But the bottom-line beat came with an asterisk.

Here's How Exact Sciences Trounced Wall Street Estimates in Q4

Exact Sciences Corp (EXAS) CEO Kevin Conroy on Q4 2019 Results - Earnings Call Transcript

While revenue figures are up substantially, they fell a little short of Wall Street's expectations.

Exact Sciences Reports Q4 Earnings, Barely Misses Revenue Target

Exact Sciences is the biotech firm behind the popular at-home colon cancer screening test, Cologuard. So is EXAS stock worth considering for growth investors?

Should Growth Investors Buy this Cancer Screening Biotech Stock?

Exact Sciences' (EXAS) Q4 performance is likely to have benefited from developments in business segments.

What's in the Cards for Exact Sciences' (EXAS) Q4 Earnings?

Exact Sciences (EXAS) closed the most recent trading day at $94.56, moving +1.37% from the previous trading session.

Exact Sciences (EXAS) Outpaces Stock Market Gains: What You Should Know

Veracyte

Genome testing is exploding on a global level; these companies are saving lives and making money.

2 Top Genome Testing Stocks for Your Watch List

Exact Sciences (EXAS) closed the most recent trading day at $87.93, moving -1.83% from the previous trading session.

Exact Sciences (EXAS) Dips More Than Broader Markets: What You Should Know

One just wrapped up a multi-billion-dollar acquisition while the other elected to remain independent.

Better Buy: Exact Sciences vs. Qiagen

After a successful 2019, the diagnostics company faces new growth opportunities with both Cologuard and its cancer-diagnostics pipeline.

How Should Investors Approach Exact Sciences in 2020?

Potential competitors for its colon cancer test Cologuard aren't ready for prime time.

Here's Why Exact Sciences Jumped Higher Today

Exact Sciences (EXAS) revenue growth will likely beat expectations for both the fourth quarter and 2019.

Exact Sciences (EXAS) Provides Q4 Expectations, Stock Falls

Karyopharm Therapeutics

PLDT

AquaVenture Holdings

Top Ranked Momentum Stocks to Buy for January 13th

Top Ranked Momentum Stocks to Buy for January 13th.

Sales of its legacy business were up 61% year over over while revenue from recently-acquired Genomic Health grew 13%.

Exact Sciences Reports Fourth Quarter Preliminary Results

Global Blood Therapeutics

CarMax

Lennar

L3Harris

Noble Energy

Cloudflare

Despite the level of uncertainty as we enter 2020, we've found seven stocks that look like the new decade’s showstoppers.

7 Stocks That Are Screaming Buys Right Now

ABIOMED

Accelerate Diagnostics

DexCom

Neurocrine Biosciences

NeoGenomics

Repligen

Simulations Plus

The 10 Best Healthcare Stocks of the Decade

Exact Sciences (EXAS) continues to make a notable progress with its Cologuard business.

News for Exact Sciences Stock (EXAS)